Jump to content


Hang onto your hat: Sclero Forums Upgrade May 14-21, 2017!! The Forums will be offline for up to 4 days, and then will return with an entirely new look and feel.


Abbott Seeks U.S. And E.U. Regulatory Approval For Humira® (adalimumab) In Psoriasis


  • Please log in to reply
No replies to this topic

#1 Guest_Jude the Grouch_*

Guest_Jude the Grouch_*
  • Guests

Posted 15 May 2007 - 07:23 PM

Abbott Seeks U.S. And E.U. Regulatory Approval For HUMIRA® (Adalimumab) In Psoriasis. Psoriasis is a non-contagious, chronic autoimmune disease that causes the body to attack itself and create raised, inflamed, scaly, red skin lesions known as plaques, which may crack and bleed. The global submissions are based on the results of two double-blind, placebo-controlled trials of HUMIRA - REVEAL and CHAMPION. In both trials, reduction in disease activity was determined. Medical News Today. 04/02/07. (Also see: Psoriasis)